Ralliant Corporation (NYSE:RAL) Sees Significant Decrease in Short Interest

Ralliant Corporation (NYSE:RAL) was the target of a significant decrease in short interest during the month of January. As of January 15th, there was short interest totaling 2,361,505 shares, a decrease of 14.4% from the December 31st total of 2,758,217 shares. Approximately 2.1% of the company’s shares are short sold. Based on an average daily volume of 1,039,281 shares, the days-to-cover ratio is currently 2.3 days. Based on an average daily volume of 1,039,281 shares, the days-to-cover ratio is currently 2.3 days. Approximately 2.1% of the company’s shares are short sold.

Ralliant Stock Performance

Shares of RAL opened at $53.39 on Tuesday. The firm has a market cap of $6.02 billion and a P/E ratio of 42.04. Ralliant has a twelve month low of $40.70 and a twelve month high of $55.25. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.03 and a current ratio of 1.49. The firm’s 50 day moving average price is $51.65 and its two-hundred day moving average price is $46.71.

Ralliant (NYSE:RAL) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.02. The company had revenue of $529.10 million for the quarter, compared to analyst estimates of $519.14 million. Ralliant has set its Q4 2025 guidance at 0.620-0.680 EPS.

Ralliant Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 23rd. Stockholders of record on Monday, March 9th will be given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, March 9th. Ralliant’s dividend payout ratio is currently 15.75%.

Analyst Ratings Changes

A number of equities analysts have issued reports on RAL shares. Citigroup upgraded Ralliant from a “neutral” rating to a “buy” rating and raised their target price for the stock from $53.00 to $61.00 in a report on Monday, December 8th. Truist Financial assumed coverage on shares of Ralliant in a report on Friday, December 12th. They set a “buy” rating and a $62.00 price objective for the company. Barclays increased their target price on shares of Ralliant from $59.00 to $60.00 and gave the stock an “overweight” rating in a report on Wednesday, January 7th. Royal Bank Of Canada boosted their price target on shares of Ralliant from $45.00 to $52.00 and gave the company a “sector perform” rating in a report on Friday, November 7th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Ralliant in a research note on Monday, December 29th. Six analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $58.00.

Institutional Investors Weigh In On Ralliant

A number of hedge funds and other institutional investors have recently bought and sold shares of RAL. Dodge & Cox acquired a new position in Ralliant during the 2nd quarter worth approximately $523,571,000. Viking Global Investors LP bought a new stake in shares of Ralliant in the second quarter worth $257,200,000. State Street Corp acquired a new position in Ralliant during the second quarter worth $213,096,000. Flossbach Von Storch SE bought a new position in Ralliant in the second quarter valued at $198,077,000. Finally, Norges Bank acquired a new stake in Ralliant in the 2nd quarter valued at $108,453,000.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.